Effects of Evolocumab on the Postprandial Kinetics of Apo (Apolipoprotein) B100- and B48-Containing Lipoproteins in Subjects With Type 2 Diabetes
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Effects of Evolocumab on the Postprandial Kinetics of Apo (Apolipoprotein) B100- and B48-Containing Lipoproteins in Subjects With Type 2 Diabetes
Authors
Keywords
-
Journal
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
Volume -, Issue -, Pages -
Publisher
Ovid Technologies (Wolters Kluwer Health)
Online
2020-12-24
DOI
10.1161/atvbaha.120.315446
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Remnants of the Triglyceride-Rich Lipoproteins, Diabetes, and Cardiovascular Disease
- (2020) Alan Chait et al. DIABETES
- Causes and Consequences of Hypertriglyceridemia
- (2020) Chris J. Packard et al. Frontiers in Endocrinology
- Metabolism of lipoprotein(a)
- (2020) Dick C. Chan et al. CURRENT OPINION IN LIPIDOLOGY
- PCSK9 Inhibition with alirocumab increases the catabolism of lipoprotein(a) particles in statin-treated patients with elevated lipoprotein(a)
- (2020) Gerald F. Watts et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Effects of PCSK9 inhibitors on LDL cholesterol, cardiovascular morbidity and all-cause mortality: a systematic review and meta-analysis of randomized controlled trials
- (2019) I. Dicembrini et al. JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION
- Investigation of human apoB48 metabolism using a new, integrated non-steady-state model of apoB48 and apoB100 kinetics
- (2019) E. Björnson et al. JOURNAL OF INTERNAL MEDICINE
- Cholesterol-Lowering Agents
- (2019) Robert S. Rosenson et al. CIRCULATION RESEARCH
- Role of apolipoprotein C‐III overproduction in diabetic dyslipidaemia
- (2019) Martin Adiels et al. DIABETES OBESITY & METABOLISM
- Efficacy and safety of evolocumab in individuals with type 2 diabetes mellitus: primary results of the randomised controlled BANTING study
- (2019) Robert S. Rosenson et al. DIABETOLOGIA
- Genetics, Dyslipidemia, and Cardiovascular Disease: New Insights
- (2019) Ricardo Stein et al. Current Cardiology Reports
- Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial
- (2019) Kausik K Ray et al. Lancet Diabetes & Endocrinology
- Impact of proprotein convertase subtilisin/kexin type 9 inhibition with evolocumab on the postprandial responses of triglyceride-rich lipoproteins in type II diabetic subjects
- (2019) Marja-Riitta Taskinen et al. Journal of Clinical Lipidology
- Apolipoprotein B48 metabolism in chylomicrons and very low‐density lipoproteins and its role in triglyceride transport in normo‐ and hypertriglyceridemic human subjects
- (2019) E. Björnson et al. JOURNAL OF INTERNAL MEDICINE
- Genetic Factors Explain a Major Fraction of the 50% Lower Lipoprotein(a) Concentrations in FinnsHighlights
- (2018) Gertraud Erhart et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Comparative Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition and Statins on Postprandial Triglyceride-Rich Lipoprotein MetabolismHighlights
- (2018) Dick C. Chan et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Efficacy and safety of alirocumab in individuals with type 2 diabetes mellitus with or without mixed dyslipidaemia: Analysis of the ODYSSEY LONG TERM trial
- (2018) Marja-Riitta Taskinen et al. ATHEROSCLEROSIS
- Lipoprotein lipase: Biosynthesis, regulatory factors, and its role in atherosclerosis and other diseases
- (2018) Ping-Ping He et al. CLINICA CHIMICA ACTA
- Alirocumab vs usual lipid-lowering care as add-on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY DM-DYSLIPIDEMIA randomized trial
- (2018) Kausik K. Ray et al. DIABETES OBESITY & METABOLISM
- Risk Factors, Mortality, and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2018) Aidin Rawshani et al. NEW ENGLAND JOURNAL OF MEDICINE
- Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel
- (2017) Brian A. Ference et al. EUROPEAN HEART JOURNAL
- Atherothrombotic Risk Stratification and Ezetimibe for Secondary Prevention
- (2017) Erin A. Bohula et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
- (2017) Marc S. Sabatine et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial
- (2017) Marc S Sabatine et al. Lancet Diabetes & Endocrinology
- Efficacy and Safety of the PCSK9 Inhibitor Evolocumab in Patients with Mixed Hyperlipidemia
- (2016) Robert S. Rosenson et al. CARDIOVASCULAR DRUGS AND THERAPY
- Effects of PCSK9 Inhibition With Alirocumab on Lipoprotein Metabolism in Healthy HumansClinical Perspective
- (2016) Gissette Reyes-Soffer et al. CIRCULATION
- Factorial Effects of Evolocumab and Atorvastatin on Lipoprotein MetabolismClinical Perspective
- (2016) Gerald F. Watts et al. CIRCULATION
- Triglyceride-Rich Lipoproteins and Atherosclerotic Cardiovascular Disease
- (2016) Børge G. Nordestgaard CIRCULATION RESEARCH
- Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials
- (2016) Lancet Diabetes & Endocrinology
- Inter-relationships between proprotein convertase subtilisin/kexin type 9, apolipoprotein C-III and plasma apolipoprotein B-48 transport in obese subjects: a stable isotope study in the postprandial state
- (2015) Dick C. Chan et al. CLINICAL SCIENCE
- Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
- (2015) Jennifer G. Robinson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events
- (2015) Marc S. Sabatine et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
- (2015) Christopher P. Cannon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Proprotein Convertase Subtilisin Kexin Type 9 Promotes Intestinal Overproduction of Triglyceride-Rich Apolipoprotein B Lipoproteins Through Both Low-Density Lipoprotein Receptor–Dependent and –Independent Mechanisms
- (2014) Shirya Rashid et al. CIRCULATION
- Postprandial hypertriglyceridemia as a coronary risk factor
- (2014) Jan Borén et al. CLINICA CHIMICA ACTA
- Genetics and Causality of Triglyceride-Rich Lipoproteins in Atherosclerotic Cardiovascular Disease
- (2014) Robert S. Rosenson et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia
- (2014) Dirk J. Blom et al. NEW ENGLAND JOURNAL OF MEDICINE
- Hepatic lipogenesis and a marker of hepatic lipid oxidation, predict postprandial responses of triglyceride-rich lipoproteins
- (2014) Niina Matikainen et al. Obesity
- Postprandial accumulation of chylomicrons and chylomicron remnants is determined by the clearance capacity
- (2012) Martin Adiels et al. ATHEROSCLEROSIS
- Dual Metabolic Defects Are Required to Produce Hypertriglyceridemia in Obese Subjects
- (2011) Marja-Riitta Taskinen et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Proprotein Convertase Subtilisin Kexin Type 9 Null Mice Are Protected From Postprandial Triglyceridemia
- (2009) Cédric Le May et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Extended-Release Niacin or Ezetimibe and Carotid Intima–Media Thickness
- (2009) Allen J. Taylor et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started